This clinical trial is focused on studying the condition known as Short Bowel Syndrome (SBS). This is a condition where a significant portion of the small intestine is missing or has been surgically removed, leading to difficulties in absorbing nutrients. The treatment being investigated in this study is a medication called Glepaglutide, which is administered as a solution for injection. Glepaglutide is a synthetic peptide, a type of protein, designed to help improve nutrient absorption in patients with SBS.

The purpose of this study is to evaluate the long-term safety of Glepaglutide treatment in adults who have completed a previous trial. Participants will receive Glepaglutide injections and will be monitored over a period of 104 weeks, which is approximately two years. During this time, researchers will collect information on any side effects or changes in health that occur. The study aims to ensure that Glepaglutide is safe for long-term use and to observe its effects on the participants’ health and well-being.

Throughout the study, participants will have regular check-ups to monitor their vital signs, such as heart rate and blood pressure, and to perform tests like blood work and urinalysis. These assessments will help researchers understand how the body responds to Glepaglutide over time. The study will also look at how the medication affects the need for parenteral support, which is a method of feeding that bypasses the usual process of eating and digestion. The goal is to see if Glepaglutide can reduce the amount of parenteral support needed by patients with SBS.